Glenmark Pharmaceuticals has launched the first biosimilar of the popular anti-diabetic drug, Liraglutide in India. The drug, marketed as Lirafit, is an injectable anti-diabetic medication that lowers therapy cost by 70%. It has received approval from the Drug Controller General of India and is priced at approximately Rs 100 for a standard dose of 1.2 mg per day. This launch marks Glenmark's entry into the injectable anti-diabetic market, expanding their presence in the diabetes therapy space.from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/nTVps8b
via IFTTT
